| Autor: |
Cherian P; Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute, Dasman 15462, Kuwait., Al-Khairi I; Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute, Dasman 15462, Kuwait., Abu-Farha M; Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute, Dasman 15462, Kuwait.; Department of Translational Research, Dasman Diabetes Institute, Dasman 15462, Kuwait., Alramah T; Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute, Dasman 15462, Kuwait., Albatineh AN; Faculty of Medicine, Kuwait University, Kuwait City 13110, Kuwait., Alhomaidah D; Department of Population Health, Dasman Diabetes Institute, Dasman 15462, Kuwait., Safadi F; Department of Anatomy and Neurobiology, Northeast Ohio Medical University, Rootstown, OH 44272, USA.; Rebecca D. Considine Research Institute, Akron Children Hospital, Akron, OH 44308, USA., Ali H; Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, Health Sciences Center, Kuwait University, Kuwait 15462, Kuwait., Abdul-Ghani M; Department of Translational Research, Dasman Diabetes Institute, Dasman 15462, Kuwait.; Division of Diabetes, University of Texas Health Science Center, San Antonio, TX 78030, USA., Tuomilehto J; Department of Public Health and Welfare, Finnish Institute for Health and Welfare, 00271 Helsinki, Finland.; Saudi Diabetes Research Group, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Koistinen HA; Department of Public Health and Welfare, Finnish Institute for Health and Welfare, 00271 Helsinki, Finland.; Department of Medicine, University of Helsinki and Helsinki University Hospital, P.O. Box 340, 00029 Helsinki, Finland.; Minerva Foundation Institute for Medical Research, 00290 Helsinki, Finland., Al-Mulla F; Department of Translational Research, Dasman Diabetes Institute, Dasman 15462, Kuwait., Abubaker J; Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute, Dasman 15462, Kuwait. |
| Abstrakt: |
The global incidence of Type 2 diabetes (T2D) is on the rise, fueled by factors such as obesity, sedentary lifestyles, socio-economic factors, and ethnic backgrounds. T2D is a multifaceted condition often associated with various health complications, including adverse effects on bone health. This study aims to assess key biomarkers linked to bone health and remodeling-Osteoprotegerin (OPG), Receptor Activator of Nuclear Factor Kappa-Β Ligand (RANKL), and Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB)-among individuals with diabetes while exploring the impact of ethnicity on these biomarkers. A cross-sectional analysis was conducted on a cohort of 2083 individuals from diverse ethnic backgrounds residing in Kuwait. The results indicate significantly elevated levels of these markers in individuals with T2D compared to non-diabetic counterparts, with OPG at 826.47 (405.8) pg/mL, RANKL at 9.25 (17.3) pg/mL, and GPNMB at 21.44 (7) ng/mL versus 653.75 (231.7) pg/mL, 0.21 (9.94) pg/mL, and 18.65 (5) ng/mL in non-diabetic individuals, respectively. Notably, this elevation was consistent across Arab and Asian populations, except for lower levels of RANKL observed in Arabs with T2D. Furthermore, a positive and significant correlation between OPG and GPNMB was observed regardless of ethnicity or diabetes status, with the strongest correlation (r = 0.473, p < 0.001) found among Arab individuals with T2D. Similarly, a positive and significant correlation between GPNMB and RANKL was noted among Asian individuals with T2D (r = 0.401, p = 0.001). Interestingly, a significant inverse correlation was detected between OPG and RANKL in non-diabetic Arab individuals. These findings highlight dysregulation in bone remodeling markers among individuals with T2D and emphasize the importance of considering ethnic variations in T2D-related complications. The performance of further studies is warranted to understand the underlying mechanisms and develop interventions based on ethnicity for personalized treatment approaches. |
